”Liquid biopsy”-ctDNA detection with great potential and challenges
Circulating tumor DNA (ctDNA) is now being extensively studied as it is a noninvasive ”real-time”biomarker that can provide diagnostic and prognostic information before, during treatment and at progression.These include DNA mutations, epigenetic alterations and other forms of tumor-specific abnormalities such as microsatellite instability (MSI) and loss of heterozygosity (LOH).ctDNA is of great value in the process of cancer treatment.However, up to date, there is no strict standard considering the exact biomarker because the development and progression of cancer is extremely complicated.Also, results of the studies evaluating ctDNA are not consistent due to the different detection methods and processing.The major challenge is still assay sensitivity and specificity for analysis of ctDNA.This review mainly focuses on the tumor specific DNA mutations, epigenetic alterations as well as detecting methods of ctDNA.The advantages and disadvantages will also be discussed.
Circulating tumor DNA (ctDNA) biomarker DNA mutation DNA methylation cancer
Mingwei Ma Hongcheng Zhu Chi Zhang Xinchen Sun Xianshu Gao Gang Chen
Department of Radiation Oncology,Peking University First Hospital,No.7,Xishiku Str.,Xicheng District Department of Radiation Oncology,The First Affiliated Hospital,Nanjing Medical University,300 Guangz Department of General Surgery,Affiliated Drum Tower Hospital of Nanjing University Medical School,32
国内会议
北京
英文
630-637
2016-01-09(万方平台首次上网日期,不代表论文的发表时间)